Comparative Pharmacology
Head-to-head clinical analysis: LUMISIGHT versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMISIGHT versus PEPTAVLON.
LUMISIGHT vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMISIGHT is a pegolaptamer that binds to and inhibits the vascular endothelial growth factor (VEGF), thereby reducing angiogenesis and vascular permeability in ocular tissues.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
1 mg administered intravenously as a single dose prior to identification of suspected malignant lesions during cystoscopy.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolonged up to 12-18 hours in moderate to severe renal impairment.
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Primarily renal excretion of unchanged drug (60-70%) and hepatic metabolism with biliary/fecal elimination of metabolites (20-25%). Approximately 5-10% is excreted unchanged in feces.
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent